Drägerwerk AG & Co. KGaA
0MT8.L
London Stock Exchange71.60
EUR
-0.80
- -
Drägerwerk AG & Co. KGaA
0MT8.L
(London Stock Exchange)
Recent
price
71.60
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Drägerwerk AG & Co. KGaA is a Germany-based multinational company specializing in medical and safety technology. Founded in 1889 and headquartered in Lübeck, Germany, Dräger manufactures, develops, and markets a wide range of system solutions, devices, and services for clinical and industrial applications across more than 190 countries. The company operates through two main segments: the Medical division and the Safety division. The Medical division offers products including anesthesia machines, ventilators, hospital consumables and accessories, medical gas pipeline systems, neonatal incubators, patient monitoring systems, phototherapy lights, surgical and examination lights, and hospital planning and infrastructure design. The Safety division provides respiratory protection equipment, fixed and portable gas detection systems, professional diving equipment, alcohol and drug testing devices, hazmat suits, thermal imaging cameras, rescue and escape equipment, and related safety technologies. Recent major developments include strategic partnerships such as the 2024 collaboration with Tata Elxsi to advance critical care innovation in India and alliances with institutions like Yashoda Medicity for large modular ICU setups incorporating cutting-edge medical gas management systems. Dräger has also expanded geographically and operationally, including plans to acquire land for a new production facility in North East England announced in 2024. The company continues to innovate in medical technology, launching predictive software solutions like BiliPredics to enhance neonatal care. Dräger maintains significant research and development investments, spending over €333 million in 2024, underscoring its commitment to advancing connected health technologies and patient monitoring. The company also actively pursues acquisitions to strengthen its technology portfolio, including the purchase of the Swiss medtech startup STIMIT AG to develop non-invasive therapies. Drägerwerk serves diverse industries including healthcare providers with acute point-of-care solutions, resource extraction, chemical and oil and gas industries, fire and rescue services, and industrial safety markets worldwide. With manufacturing and development sites across multiple countries and subsidiaries in approximately 50 countries, the company operates a global sales and service network. Dräger’s comprehensive product portfolio and recent strategic initiatives position it as a leading innovator in both medical and safety technology sectors globally.